JAGXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Jaguar Health, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026

$2.82−0.71 (-20.00%)

Close on Oct 19, 2026

Market cap: $2.28M
P/E (TTM): –
Dividend yield: –

SEC filings

40 of Jaguar Health's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Proxy statement	DEF 14A	Nov 6, 2026	Oct 8, 2026	SEC EDGAR
Current report	8-K	Sep 30, 2026	Oct 5, 2026	SEC EDGAR
Current report	8-K	Sep 25, 2026	Sep 28, 2026	SEC EDGAR
Current report	8-K	Sep 23, 2026	Sep 25, 2026	SEC EDGAR
Current report	8-K	Sep 23, 2026	Sep 24, 2026	SEC EDGAR
Current report	8-K	Sep 15, 2026	Sep 21, 2026	SEC EDGAR
Current report	8-K	Sep 11, 2026	Sep 15, 2026	SEC EDGAR
Current report	8-K	Sep 14, 2026	Sep 15, 2026	SEC EDGAR
Current report	8-K	Sep 4, 2026	Sep 4, 2026	SEC EDGAR
Current report	8-K	Aug 19, 2026	Aug 19, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 19, 2026	SEC EDGAR
Proxy statement	DEF 14A	Sep 4, 2026	Aug 3, 2026	SEC EDGAR
Current report	8-K	Jul 9, 2026	Jul 14, 2026	SEC EDGAR
Current report	8-K	Jul 1, 2026	Jul 1, 2026	SEC EDGAR
Current report	8-K	Jun 22, 2026	Jun 25, 2026	SEC EDGAR
Current report	8-K	Jun 22, 2026	Jun 22, 2026	SEC EDGAR
Current report	8-K	Jun 17, 2026	Jun 18, 2026	SEC EDGAR
Current report	8-K	Jun 8, 2026	Jun 11, 2026	SEC EDGAR
Current report	8-K	Jun 8, 2026	Jun 8, 2026	SEC EDGAR
Current report	8-K	Jun 1, 2026	Jun 2, 2026	SEC EDGAR
Current report	8-K	May 26, 2026	May 27, 2026	SEC EDGAR
Current report	8-K	May 21, 2026	May 22, 2026	SEC EDGAR
Current report	8-K	May 20, 2026	May 20, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 20, 2026	SEC EDGAR
Current report	8-K	May 19, 2026	May 19, 2026	SEC EDGAR
Current report	8-K	May 6, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 4, 2026	May 4, 2026	SEC EDGAR
Current report	8-K	May 1, 2026	May 4, 2026	SEC EDGAR
Proxy statement	DEF 14A	May 22, 2026	Apr 30, 2026	SEC EDGAR
Current report	8-K	Apr 24, 2026	Apr 27, 2026	SEC EDGAR
Current report	8-K	Apr 20, 2026	Apr 21, 2026	SEC EDGAR
Current report	8-K	Apr 7, 2026	Apr 9, 2026	SEC EDGAR
Current report	8-K	Apr 7, 2026	Apr 7, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Apr 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 20, 2026	Mar 24, 2026	SEC EDGAR
Current report	8-K	Mar 6, 2026	Mar 9, 2026	SEC EDGAR
Current report	8-K	Mar 5, 2026	Mar 6, 2026	SEC EDGAR
Current report	8-K	Mar 2, 2026	Mar 3, 2026	SEC EDGAR
Current report	8-K	Feb 18, 2026	Feb 18, 2026	SEC EDGAR
Current report	8-K	Jan 16, 2026	Jan 23, 2026	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Jaguar Health's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Sep 17, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is JAGX.

Revenue growth135.5% · median -16.4%

Gross margin82.3% · median 65.4%

Operating margin-93.1% · median -56.3%

Net margin-192.6% · median -51.4%

Company	Revenue	Growth
ZOMDF	$36.88M	+30.1%
JAGX	$27.82M	+135.5%
CELU	$18.97M	-62.8%
EMMA	$15.53M	–
BHST	–	–
PTCHF	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 47
Auditor: RBSM LLP
SEC CIK: 1585608

Advertisement
300 × 250